MCC: TB and HIV
- National TB-HIV Collaborative Framework
- Intensified TB Case Finding [ICF] in HIV testing Settings
- HIV testing of individuals with presumed or confirmed TB
- ART For TB-HIV Patients
- Immune Reconstitution Inflammatory Syndrome [IRIS]
- Co-trimoxazole prophylactic therapy in persons with HIV and TB coinfection
- Isoniazid Preventive Therapy [IPT] in People Living with HIV [PLHIV]
- Linkage to TB-HIV services in the private sector
- Prevention of TB in facilities caring for HIV-infected persons
M4-MCC: TB Treatment and care
- MCC: General Concepts in TB Treatment
- MCC: DS-TB Treatment and Care
- MCC: DR-TB Treatment and care
- MCC: Isoniazid [H] Mono/Poly DR-TB Regimen
- MCC: Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen
- MCC: Longer Oral M/XDR-TB Regimen
- MCC: Treatment Support
- MCC: Adherence Management
- MCC: ADRs to ATT
- MCC: Monitoring of Treatment
MCC: Monitoring of Treatment
- Monitoring indicator for TB Treatment outcome
- Monitoring indicators related to DR-TB Treatment
- NTEP Performance Indicator - Treatment Success Rate
- NTEP Performance Indicator – Percentage Of Multidrug-resistant [MDR]/ Rifampicin-resistant [RR] Patients Initiated on Treatment Out of Totally Diagnosed
- RCA for low performance in in Percentage Treatment initiation of RR/MDR-TB Cases
- DR-TB Treatment Register
- Follow-Up Register
- DRTB Follow Up Register
MCC: ADRs to ATT
- Adverse Drug Reactions [ADRs]
- Types of ADR of TB Treatment
- Management of Adverse Drug Reactions [ADRs] of TB Treatment
- Pharmacovigilance in NTEP
- Possible Adverse Events Due to Drugs in Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen
- Adverse Drug Reactions due to Longer oral M/XDR-TB Regimen
- Adverse Drug Events: H Mono/Poly DR-TB Regimen
- ADRs to Second Line Treatment
- Management of ADR: Rash, Allergy and Anaphylaxis Reaction
- Management of DR-TB ADR: Gastritis, abdominal pain
- Management of DR-TB ADR: Diarrhoea and/or Flatulence
- Management of DR-TB ADR: Hepatitis
- Management of DR-TB ADR: Giddiness
- Management of DR-TB ADR: QT Prolongation
- Management of DR-TB ADR: Hematological Abnormalities
- Management of DR-TB ADR: Hypothyroidism
- Management of DR-TB ADR: Arthralgia
- Management of DR-TB ADR: Peripheral Neuropathy
- Management of DR-TB ADR: Psychotic Symptoms
- Management of DR-TB ADR: Nephrotoxicity [Renal Toxicity]
- Management of DR-TB ADR: Vestibular Toxicity